"Beware of Colds~" Panpillin Supply Price to Increase by 12.5% Starting October

[Asia Economy Reporter Lee Gwan-joo] Amid ongoing inflationary pressures, the price of 'Panpyrin,' a leading cold medicine in South Korea, will rise for the first time in five years.

According to the pharmaceutical industry on the 12th, Dong-A Pharmaceutical has decided to increase the pharmacy supply price of Panpyrin by 12.5% starting this October. This price hike is the first since September 2017. The company explained that the price increase was inevitable due to the continued burden of rising production costs.

Panpyrin, launched in 1961, is an over-the-counter cold medicine familiar to the public through the advertisement slogan "Be careful of colds." Panpyrin is currently supplied in two categories: for pharmacies and for convenience stores, and this price increase applies to the Panpyrin supplied to pharmacies.

Following the increase in supply price, the retail price at pharmacies is also expected to rise. The supply price is the price applied when the pharmaceutical company delivers the product to pharmacies. Currently, over-the-counter medicines are subject to a seller price display system, allowing each pharmacy to autonomously set and sell the retail price, so the final price consumers pay varies by pharmacy.

Unable to withstand rising raw material costs, a considerable number of pharmaceutical companies have already implemented price increases for their main products. This year, supply price hikes have been decided for Ildong Pharmaceutical's 'Aronamin C Plus,' GC Green Cross's 'Genol Cool,' and Ilyang Pharmaceutical's 'Wonbidi,' among others.

This content was produced with the assistance of AI translation services.